MX2017011824A - Derivado de morfinano. - Google Patents
Derivado de morfinano.Info
- Publication number
- MX2017011824A MX2017011824A MX2017011824A MX2017011824A MX2017011824A MX 2017011824 A MX2017011824 A MX 2017011824A MX 2017011824 A MX2017011824 A MX 2017011824A MX 2017011824 A MX2017011824 A MX 2017011824A MX 2017011824 A MX2017011824 A MX 2017011824A
- Authority
- MX
- Mexico
- Prior art keywords
- represent hydrogen
- ring
- atoms
- carbon atoms
- carbon atom
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000004429 atom Chemical group 0.000 abstract 3
- 239000000470 constituent Substances 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un derivado de morfinano representado por la siguiente fórmula general (I): (ver Fórmula) en donde R1 representa hidrógeno, alquilo de C1-10, cicloalquilalquilo donde la porción cicloalquilo tiene de 3 a 6 átomos de carbono, y la porción alquileno tiene de 1 a 5 átomos de carbono, etc., R2 representa un anillo heterocíclico que contiene de 1 a 4 heteroátomos seleccionados de N, O y S y al menos un átomo de carbono como los átomos constituyentes del anillo, que contienen al menos un conjunto de átomos constituyentes del anillo adyacentes unidos mediante un doble enlace, y sustituidos adicionalmente con al menos un grupo oxo, Y se une a un átomo de carbono como un átomo constituyente del anillo de R2, R3, R4, y R5 representan hidrógeno; hidroxi, etc., y R6a y R6b representan hidrógeno, etc., R7 y R8 representan hidrógeno, etc., R9 y R10, que son iguales o diferentes, representan hidrógeno, etc., X representa O o CH2, y Y representa C(=O)), un tautómero o un estereoisómero del compuesto, o una sal farmacéuticamente aceptable del mismo, o un solvato del mismo se utilizó como un fármaco ansiolítico, antidepresivo, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015054079 | 2015-03-17 | ||
| PCT/JP2016/058475 WO2016148232A1 (ja) | 2015-03-17 | 2016-03-17 | モルヒナン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011824A true MX2017011824A (es) | 2018-04-20 |
| MX384744B MX384744B (es) | 2025-03-14 |
Family
ID=56919074
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008741A MX2021008741A (es) | 2015-03-17 | 2016-03-17 | Metodo para preparar un derivado de morfinano. |
| MX2017011824A MX384744B (es) | 2015-03-17 | 2016-03-17 | Derivado de morfinano. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008741A MX2021008741A (es) | 2015-03-17 | 2016-03-17 | Metodo para preparar un derivado de morfinano. |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10442802B2 (es) |
| EP (2) | EP3974430A1 (es) |
| JP (5) | JP6692345B2 (es) |
| KR (2) | KR102813010B1 (es) |
| CN (3) | CN107614500B (es) |
| AU (2) | AU2016234222C1 (es) |
| BR (1) | BR112017019805B1 (es) |
| CA (1) | CA2979023C (es) |
| CY (1) | CY1124908T1 (es) |
| DK (1) | DK3272750T3 (es) |
| ES (1) | ES2904511T3 (es) |
| HU (1) | HUE057266T2 (es) |
| IL (1) | IL254473B (es) |
| MA (1) | MA41790B1 (es) |
| MX (2) | MX2021008741A (es) |
| MY (1) | MY197742A (es) |
| PH (1) | PH12017501655B1 (es) |
| PL (1) | PL3272750T3 (es) |
| RU (1) | RU2762567C2 (es) |
| SG (2) | SG10201907667RA (es) |
| TW (2) | TWI778933B (es) |
| WO (1) | WO2016148232A1 (es) |
| ZA (1) | ZA201706882B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017019805B1 (pt) * | 2015-03-17 | 2023-01-31 | Nippon Chemiphar Co., Ltd | Composto, composição farmacêutica, e uso para fabricar uma composição farmacêutica para melhorar, prevenir ou tratar dor, ansiedade ou depressão, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma |
| EP3498711A4 (en) | 2016-08-09 | 2020-01-22 | Nippon Chemiphar Co., Ltd. | morphinan |
| EP3513792B9 (en) * | 2016-09-16 | 2024-07-10 | Nippon Chemiphar Co., Ltd. | Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases |
| JP7283711B2 (ja) * | 2016-10-03 | 2023-05-30 | 学校法人星薬科大学 | モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用 |
| AU2020318159A1 (en) * | 2019-07-19 | 2022-02-10 | Nippon Chemiphar Co., Ltd. | Method for producing morphinan derivative |
| CN114127069A (zh) | 2019-07-19 | 2022-03-01 | 日本化学药品株式会社 | 苯酚衍生物的制造方法 |
| KR20230044470A (ko) | 2020-08-28 | 2023-04-04 | 닛뽕 케미파 가부시키가이샤 | 신규한 구리 촉매를 사용하여 디아릴 에테르 골격을 갖는 모르피난 유도체를 제조하는 방법 |
| WO2022181763A1 (ja) * | 2021-02-26 | 2022-09-01 | 学校法人東京理科大学 | ストレス関連障害の治療又は予防用医薬組成物 |
| CN116997360A (zh) * | 2021-02-26 | 2023-11-03 | 学校法人东京理科大学 | 应激相关障碍的治疗或预防用医药组合物 |
| WO2025197843A1 (ja) * | 2024-03-18 | 2025-09-25 | 学校法人東京理科大学 | アンヘドニアの治療又は予防用医薬組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| DE10161963A1 (de) | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| AR044010A1 (es) | 2003-04-11 | 2005-08-24 | Janssen Pharmaceutica Nv | Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica |
| EP1869045A1 (en) | 2005-04-04 | 2007-12-26 | AstraZeneca AB | Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases |
| WO2008001859A1 (fr) | 2006-06-30 | 2008-01-03 | School Juridical Person Kitasato Gakuen | AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES |
| US20110130406A1 (en) | 2007-09-06 | 2011-06-02 | Array Biopharma Inc. | Pyrazolo-pyridines as tyrosine kinase inhibitors |
| RU2543484C2 (ru) | 2009-10-30 | 2015-03-10 | Янссен Фармацевтика Нв | Пиразины для использования в качестве модуляторов дельта-опиоидных рецепторов |
| US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
| JP6091426B2 (ja) | 2010-12-23 | 2017-03-08 | フェニックス ファーマラブス インク | 鎮痛剤として有用な新規モルフィナン類 |
| JP2014073964A (ja) | 2011-01-28 | 2014-04-24 | Kitasato Institute | モルヒナン誘導体 |
| JP6061857B2 (ja) * | 2011-09-09 | 2017-01-18 | 学校法人北里研究所 | モルヒナン誘導体 |
| WO2014021273A1 (ja) | 2012-07-30 | 2014-02-06 | 学校法人北里研究所 | モルヒナン誘導体 |
| US8937084B2 (en) | 2012-12-14 | 2015-01-20 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
| JP6173431B2 (ja) | 2013-03-08 | 2017-08-02 | 学校法人北里研究所 | モルヒナン誘導体 |
| BR112017019805B1 (pt) * | 2015-03-17 | 2023-01-31 | Nippon Chemiphar Co., Ltd | Composto, composição farmacêutica, e uso para fabricar uma composição farmacêutica para melhorar, prevenir ou tratar dor, ansiedade ou depressão, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma |
| EP3513792B9 (en) | 2016-09-16 | 2024-07-10 | Nippon Chemiphar Co., Ltd. | Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases |
-
2016
- 2016-03-17 BR BR112017019805-3A patent/BR112017019805B1/pt active IP Right Grant
- 2016-03-17 RU RU2017134286A patent/RU2762567C2/ru active
- 2016-03-17 PL PL16765061T patent/PL3272750T3/pl unknown
- 2016-03-17 SG SG10201907667RA patent/SG10201907667RA/en unknown
- 2016-03-17 CN CN201680016083.0A patent/CN107614500B/zh active Active
- 2016-03-17 DK DK16765061.3T patent/DK3272750T3/da active
- 2016-03-17 KR KR1020237022162A patent/KR102813010B1/ko active Active
- 2016-03-17 CN CN202110578658.0A patent/CN113292559B/zh active Active
- 2016-03-17 JP JP2017506606A patent/JP6692345B2/ja active Active
- 2016-03-17 US US15/558,026 patent/US10442802B2/en active Active
- 2016-03-17 KR KR1020177029778A patent/KR102551969B1/ko active Active
- 2016-03-17 MY MYPI2017703345A patent/MY197742A/en unknown
- 2016-03-17 SG SG11201707427TA patent/SG11201707427TA/en unknown
- 2016-03-17 HU HUE16765061A patent/HUE057266T2/hu unknown
- 2016-03-17 EP EP21203556.2A patent/EP3974430A1/en active Pending
- 2016-03-17 MA MA41790A patent/MA41790B1/fr unknown
- 2016-03-17 MX MX2021008741A patent/MX2021008741A/es unknown
- 2016-03-17 AU AU2016234222A patent/AU2016234222C1/en active Active
- 2016-03-17 TW TW111126713A patent/TWI778933B/zh active
- 2016-03-17 MX MX2017011824A patent/MX384744B/es unknown
- 2016-03-17 CA CA2979023A patent/CA2979023C/en active Active
- 2016-03-17 EP EP16765061.3A patent/EP3272750B1/en active Active
- 2016-03-17 WO PCT/JP2016/058475 patent/WO2016148232A1/ja not_active Ceased
- 2016-03-17 TW TW105108248A patent/TWI775723B/zh active
- 2016-03-17 ES ES16765061T patent/ES2904511T3/es active Active
- 2016-03-17 CN CN202110577382.4A patent/CN113292558A/zh active Pending
-
2017
- 2017-09-11 PH PH12017501655A patent/PH12017501655B1/en unknown
- 2017-09-13 IL IL254473A patent/IL254473B/en unknown
- 2017-10-11 ZA ZA2017/06882A patent/ZA201706882B/en unknown
-
2019
- 2019-07-19 US US16/517,081 patent/US10995092B2/en active Active
-
2020
- 2020-04-10 JP JP2020071041A patent/JP2020117533A/ja not_active Ceased
- 2020-10-13 US US17/069,589 patent/US11643411B2/en active Active
- 2020-11-18 AU AU2020270503A patent/AU2020270503C9/en active Active
-
2022
- 2022-01-18 CY CY20221100041T patent/CY1124908T1/el unknown
- 2022-03-18 JP JP2022044083A patent/JP7375076B2/ja active Active
-
2023
- 2023-01-09 US US18/094,687 patent/US20230159530A1/en active Pending
- 2023-10-25 JP JP2023183221A patent/JP2024010098A/ja active Pending
-
2025
- 2025-06-10 JP JP2025096247A patent/JP2025131782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011824A (es) | Derivado de morfinano. | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR109349A1 (es) | Compuestos y usos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR092269A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX2016015641A (es) | Compuesto de pirrolidina novedoso, y aplicación como agonista del receptor de melanocortina. | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| CO6420340A2 (es) | Derivados de benzofurano | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| ES2586527T3 (es) | Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| CO2018010787A2 (es) | Compuesto de griseofulvina | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| MX2017011650A (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| CR20160562A (es) | Péptidos como agonistas de la oxitocina | |
| MA50093B1 (fr) | Composé pentacyclique | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| CL2021000454A1 (es) | Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina | |
| AR109712A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |